- Home
- CLDX
as 12-26-2024 4:00pm EST
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | HAMPTON |
| Market Cap: | 1.8B | IPO Year: | 2008 |
| Target Price: | $64.83 | AVG Volume (30 days): | 914.2K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.93 - $53.18 | Next Earning Date: | 02-24-2025 |
| Revenue: | $9,976,000 | Revenue Growth: | 128.55% |
| Revenue Growth (this year): | -7.99% | Revenue Growth (next year): | -41.29% |
Stock Insider Trading Activity of Celldex Therapeutics Inc. (CLDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Marucci Anthony S | CLDX | PRESIDENT & CEO | Nov 11 '24 | Buy | $26.82 | 11,500 | $308,430.00 | 40,284 |
Latest Celldex Therapeutics Inc. News
CLDX Breaking Stock News: Dive into CLDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Zacks
14 days ago
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
MT Newswires
a month ago
Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment
GlobeNewswire
a month ago
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
GlobeNewswire
a month ago
Celldex Therapeutics to Present at Upcoming Investor Conferences
Simply Wall St.
2 months ago
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
2 months ago
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
2 months ago
Celldex: Q3 Earnings Snapshot
Compare CLDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLDX Celldex Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.